Case Report: Giant Paraganglioma of the Skull Base With Two Somatic Mutations in SDHB and PTEN Genes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Case Report : Giant Paraganglioma of the Skull Base With Two Somatic Mutations in SDHB and PTEN Genes. / Main, Ailsa Maria; Benndorf, Götz; Feldt-Rasmussen, Ulla; Fugleholm, Kåre; Kistorp, Thomas; Loya, Anand C.; Poulsgaard, Lars; Rasmussen, Åse Krogh; Rossing, Maria; Sølling, Christine; Klose, Marianne Christina.

I: Frontiers in Endocrinology, Bind 13, 857504, 2022.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Main, AM, Benndorf, G, Feldt-Rasmussen, U, Fugleholm, K, Kistorp, T, Loya, AC, Poulsgaard, L, Rasmussen, ÅK, Rossing, M, Sølling, C & Klose, MC 2022, 'Case Report: Giant Paraganglioma of the Skull Base With Two Somatic Mutations in SDHB and PTEN Genes', Frontiers in Endocrinology, bind 13, 857504. https://doi.org/10.3389/fendo.2022.857504

APA

Main, A. M., Benndorf, G., Feldt-Rasmussen, U., Fugleholm, K., Kistorp, T., Loya, A. C., Poulsgaard, L., Rasmussen, Å. K., Rossing, M., Sølling, C., & Klose, M. C. (2022). Case Report: Giant Paraganglioma of the Skull Base With Two Somatic Mutations in SDHB and PTEN Genes. Frontiers in Endocrinology, 13, [857504]. https://doi.org/10.3389/fendo.2022.857504

Vancouver

Main AM, Benndorf G, Feldt-Rasmussen U, Fugleholm K, Kistorp T, Loya AC o.a. Case Report: Giant Paraganglioma of the Skull Base With Two Somatic Mutations in SDHB and PTEN Genes. Frontiers in Endocrinology. 2022;13. 857504. https://doi.org/10.3389/fendo.2022.857504

Author

Main, Ailsa Maria ; Benndorf, Götz ; Feldt-Rasmussen, Ulla ; Fugleholm, Kåre ; Kistorp, Thomas ; Loya, Anand C. ; Poulsgaard, Lars ; Rasmussen, Åse Krogh ; Rossing, Maria ; Sølling, Christine ; Klose, Marianne Christina. / Case Report : Giant Paraganglioma of the Skull Base With Two Somatic Mutations in SDHB and PTEN Genes. I: Frontiers in Endocrinology. 2022 ; Bind 13.

Bibtex

@article{875ff081037645a5b6113d054a1db5f2,
title = "Case Report: Giant Paraganglioma of the Skull Base With Two Somatic Mutations in SDHB and PTEN Genes",
abstract = "Head and neck paragangliomas (HNPGLs) are neuroendocrine tumors. They arise from the parasympathetic ganglia and can be either sporadic or due to hereditary syndromes (up to 40%). Most HNPGLs do not produce significant amounts of catecholamines. We report a case of a giant paraganglioma of the skull base with an unusually severe presentation secondary to excessive release of norepinephrine, with a good outcome considering the severity of disease. A 39-year-old Caucasian woman with no prior medical history was found unconscious and emaciated in her home. In the intensive care unit (ICU) the patient was treated for multi-organ failure with multiple complications and difficulties in stabilizing her blood pressure with values up to 246/146 mmHg. She was hospitalized in the ICU for 72 days and on the 31st day clinical assessment revealed jugular foramen syndrome and paralysis of the right n. facialis. A brain MRI confirmed a right-sided tumor of the skull base of 93.553 cm3. Blood tests showed high amounts of normetanephrine (35.1-45.4 nmol/L, ref <1.09 nmol/L) and a tumor biopsy confirmed the diagnosis of a paraganglioma. Phenoxybenzamine and Labetalol were used in high doses ((Dibenyline{\textregistered}, 90 mg x 3 daily) and labetalol (Trandate{\textregistered}, 200 + 300 + 300 mg daily) to stabilize blood pressure. The patient underwent two tumor embolization procedures before total tumor resection on day 243. Normetanephrine and blood pressure normalized after surgery (0.77 nmol/L, ref: < 1.09 nmol/L). The damage to the cranial nerve was permanent. Our patient was comprehensively examined for germline predisposition to PPGLs, however we did not identify any causal aberrations. A somatic deletion and loss of heterozygosity (LOH) of the short arm (p) of chromosome 1 (including SDHB) and p of chromosome 11 was found. Analysis showed an SDHB (c.565T>G, p.C189G) and PTEN (c.834C>G, p.F278L) missense mutation in tumor DNA. The patient made a remarkable recovery except for neurological deficits after intensive multidisciplinary treatment and rehabilitation. This case demonstrates the necessity for an early tertiary center approach with a multidisciplinary expert team and highlights the efficacy of the correct treatment with alpha-blockade.",
keywords = "alpha blockade, catecholamine, Head and neck paraganglioma (HNPGL), multidisciplinary approach, neuroendochrine tumor, paraganglioglioma, rehabilitation, SDHB gene",
author = "Main, {Ailsa Maria} and G{\"o}tz Benndorf and Ulla Feldt-Rasmussen and K{\aa}re Fugleholm and Thomas Kistorp and Loya, {Anand C.} and Lars Poulsgaard and Rasmussen, {{\AA}se Krogh} and Maria Rossing and Christine S{\o}lling and Klose, {Marianne Christina}",
note = "Publisher Copyright: Copyright {\textcopyright} 2022 Main, Benndorf, Feldt-Rasmussen, Fugleholm, Kistorp, Loya, Poulsgaard, Rasmussen, Rossing, S{\o}lling and Klose.",
year = "2022",
doi = "10.3389/fendo.2022.857504",
language = "English",
volume = "13",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S.A.",

}

RIS

TY - JOUR

T1 - Case Report

T2 - Giant Paraganglioma of the Skull Base With Two Somatic Mutations in SDHB and PTEN Genes

AU - Main, Ailsa Maria

AU - Benndorf, Götz

AU - Feldt-Rasmussen, Ulla

AU - Fugleholm, Kåre

AU - Kistorp, Thomas

AU - Loya, Anand C.

AU - Poulsgaard, Lars

AU - Rasmussen, Åse Krogh

AU - Rossing, Maria

AU - Sølling, Christine

AU - Klose, Marianne Christina

N1 - Publisher Copyright: Copyright © 2022 Main, Benndorf, Feldt-Rasmussen, Fugleholm, Kistorp, Loya, Poulsgaard, Rasmussen, Rossing, Sølling and Klose.

PY - 2022

Y1 - 2022

N2 - Head and neck paragangliomas (HNPGLs) are neuroendocrine tumors. They arise from the parasympathetic ganglia and can be either sporadic or due to hereditary syndromes (up to 40%). Most HNPGLs do not produce significant amounts of catecholamines. We report a case of a giant paraganglioma of the skull base with an unusually severe presentation secondary to excessive release of norepinephrine, with a good outcome considering the severity of disease. A 39-year-old Caucasian woman with no prior medical history was found unconscious and emaciated in her home. In the intensive care unit (ICU) the patient was treated for multi-organ failure with multiple complications and difficulties in stabilizing her blood pressure with values up to 246/146 mmHg. She was hospitalized in the ICU for 72 days and on the 31st day clinical assessment revealed jugular foramen syndrome and paralysis of the right n. facialis. A brain MRI confirmed a right-sided tumor of the skull base of 93.553 cm3. Blood tests showed high amounts of normetanephrine (35.1-45.4 nmol/L, ref <1.09 nmol/L) and a tumor biopsy confirmed the diagnosis of a paraganglioma. Phenoxybenzamine and Labetalol were used in high doses ((Dibenyline®, 90 mg x 3 daily) and labetalol (Trandate®, 200 + 300 + 300 mg daily) to stabilize blood pressure. The patient underwent two tumor embolization procedures before total tumor resection on day 243. Normetanephrine and blood pressure normalized after surgery (0.77 nmol/L, ref: < 1.09 nmol/L). The damage to the cranial nerve was permanent. Our patient was comprehensively examined for germline predisposition to PPGLs, however we did not identify any causal aberrations. A somatic deletion and loss of heterozygosity (LOH) of the short arm (p) of chromosome 1 (including SDHB) and p of chromosome 11 was found. Analysis showed an SDHB (c.565T>G, p.C189G) and PTEN (c.834C>G, p.F278L) missense mutation in tumor DNA. The patient made a remarkable recovery except for neurological deficits after intensive multidisciplinary treatment and rehabilitation. This case demonstrates the necessity for an early tertiary center approach with a multidisciplinary expert team and highlights the efficacy of the correct treatment with alpha-blockade.

AB - Head and neck paragangliomas (HNPGLs) are neuroendocrine tumors. They arise from the parasympathetic ganglia and can be either sporadic or due to hereditary syndromes (up to 40%). Most HNPGLs do not produce significant amounts of catecholamines. We report a case of a giant paraganglioma of the skull base with an unusually severe presentation secondary to excessive release of norepinephrine, with a good outcome considering the severity of disease. A 39-year-old Caucasian woman with no prior medical history was found unconscious and emaciated in her home. In the intensive care unit (ICU) the patient was treated for multi-organ failure with multiple complications and difficulties in stabilizing her blood pressure with values up to 246/146 mmHg. She was hospitalized in the ICU for 72 days and on the 31st day clinical assessment revealed jugular foramen syndrome and paralysis of the right n. facialis. A brain MRI confirmed a right-sided tumor of the skull base of 93.553 cm3. Blood tests showed high amounts of normetanephrine (35.1-45.4 nmol/L, ref <1.09 nmol/L) and a tumor biopsy confirmed the diagnosis of a paraganglioma. Phenoxybenzamine and Labetalol were used in high doses ((Dibenyline®, 90 mg x 3 daily) and labetalol (Trandate®, 200 + 300 + 300 mg daily) to stabilize blood pressure. The patient underwent two tumor embolization procedures before total tumor resection on day 243. Normetanephrine and blood pressure normalized after surgery (0.77 nmol/L, ref: < 1.09 nmol/L). The damage to the cranial nerve was permanent. Our patient was comprehensively examined for germline predisposition to PPGLs, however we did not identify any causal aberrations. A somatic deletion and loss of heterozygosity (LOH) of the short arm (p) of chromosome 1 (including SDHB) and p of chromosome 11 was found. Analysis showed an SDHB (c.565T>G, p.C189G) and PTEN (c.834C>G, p.F278L) missense mutation in tumor DNA. The patient made a remarkable recovery except for neurological deficits after intensive multidisciplinary treatment and rehabilitation. This case demonstrates the necessity for an early tertiary center approach with a multidisciplinary expert team and highlights the efficacy of the correct treatment with alpha-blockade.

KW - alpha blockade

KW - catecholamine

KW - Head and neck paraganglioma (HNPGL)

KW - multidisciplinary approach

KW - neuroendochrine tumor

KW - paraganglioglioma

KW - rehabilitation

KW - SDHB gene

UR - http://www.scopus.com/inward/record.url?scp=85128975975&partnerID=8YFLogxK

U2 - 10.3389/fendo.2022.857504

DO - 10.3389/fendo.2022.857504

M3 - Journal article

C2 - 35498434

AN - SCOPUS:85128975975

VL - 13

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

M1 - 857504

ER -

ID: 312764788